Eiger Biopharmaceuticals Inc (EIGR)

Name: Eiger Biopharmaceuticals Inc (EIGR) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Eiger Biopharmaceuticals Inc (EIGR)

Stock Card

$2.27

$-- (--%)

As on 10-May-2024 09:30EDT

Market cap

$3 Mln

Revenue (TTM)

$16 Mln

P/E Ratio

P/B Ratio

0.9

Div. Yield

0 %

Eiger Biopharmaceuticals Inc (EIGR) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.27 High: 2.27

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-43 Mln
ROE

-2.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.3
Debt to Equity

-2.8
Book Value

$--
EPS

$-50.8
Face value

--
Shares outstanding

1,479,490

10 Years Aggregate

CFO

$-545.06 Mln

EBITDA

$-522.90 Mln

Net Profit

$-568.12 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Eiger Biopharmaceuticals Inc (EIGR)	-66.3	19.6	-60.5	-93.3	-79.3	-63.0	-53.3
BSE Sensex^*	-8.7	1.6	1.7	-4.3	6.0	6.7	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 10-May-2024 | *As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019	2018	2017
Eiger Biopharmaceuticals Inc (EIGR)	-80.9	-77.3	-57.8	-17.5	46.7	-27.0	19.7
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9	-9.7	11.7
BSE Sensex	18.7	4.4	22.0	15.8	14.4	5.9	27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Eiger Biopharmaceuticals Inc (EIGR)	2.3	2.6	15.8	-75.0	-448.6	-367	--	0.9
Acorda Therapeutics (ACOR)	0.4	0.8	133.4	-453.8	-7.7	--	--	0.1

Shareholding Pattern

View Details

About Eiger Biopharmaceuticals Inc (EIGR)

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate... is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. Read more

CEO & Director

Dr. David Apelian M.B.A., M.D., Ph.D.
CEO & Director

Dr. David Apelian M.B.A., M.D., Ph.D.
Headquarters

Palo Alto, CA
Website

https://www.eigerbio.com

FAQs for Eiger Biopharmaceuticals Inc (EIGR)

What is the current share price of Eiger Biopharmaceuticals Inc (EIGR) Today?

The share price of Eiger Biopharmaceuticals Inc (EIGR) is $2.27 (NASDAQ) as of 10-May-2024 09:30 EDT. Eiger Biopharmaceuticals Inc (EIGR) has given a return of -79.3% in the last 3 years.

What is the current PB & PE ratio of Eiger Biopharmaceuticals Inc (EIGR)?

Since, TTM earnings of Eiger Biopharmaceuticals Inc (EIGR) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	0.00	-0.02
2022	-0.02	0.03
2021	-5.20	2.44
2020	-5.35	3.86
2019	-4.96	6.46

What is the 52 Week High and Low of Eiger Biopharmaceuticals Inc (EIGR)?

The 52-week high and low of Eiger Biopharmaceuticals Inc (EIGR) are Rs -- and Rs -- as of 27-Aug-2026.

What is the market cap of Eiger Biopharmaceuticals Inc (EIGR)?

Eiger Biopharmaceuticals Inc (EIGR) has a market capitalisation of $ 3 Mln as on 10-May-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Eiger Biopharmaceuticals Inc (EIGR)?

Before investing in Eiger Biopharmaceuticals Inc (EIGR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.